Baxter International Inc.

60.46+0.4900+0.82%Vol 2.03M1Y Perf -18.81%
Aug 12th, 2022 16:00 DELAYED
BID59.47 ASK61.27
Open60.01 Previous Close59.97
Pre-Market- After-Market60.68
 - -  0.22 0.36%
Target Price
84.83 
Analyst Rating
Moderate Buy 1.75
Potential %
40.31 
Finscreener Ranking
★★+     46.87
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★     46.05
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★     52.87
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
★★     37.73
Price Range Ratio 52W %
9.22 
Earnings Rating
Sell
Market Cap30.45B 
Earnings Date
28th Jul 2022
Alpha-0.00 Standard Deviation0.07
Beta0.68 

Today's Price Range

60.0160.71

52W Range

57.4989.70

5 Year PE Ratio Range

4.9072.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.19%
1 Month
-5.21%
3 Months
-17.21%
6 Months
-29.62%
1 Year
-18.81%
3 Years
-31.44%
5 Years
1.04%
10 Years
107.16%

TickerPriceChg.Chg.%
BAX60.460.49000.82
AAPL172.123.63002.15
GOOG122.652.83002.36
MSFT291.914.89001.70
XOM94.000.81000.87
WFC45.940.69001.52
JNJ165.30-1.8400-1.10
FB196.640.99000.51
GE79.931.03001.31
JPM122.131.99001.66
 
ProfitabilityValueIndustryS&P 500US Markets
39.00
10.10
18.50
10.90
7.20
RevenueValueIndustryS&P 500US Markets
14.19B
28.18
5.10
4.36
DividendsValueIndustryS&P 500US Markets
1.93
1.16
11.70
15.15
Payout ratio46.00
Earnings HistoryEstimateReportedSurprise %
Q02 20220.880.87-1.14
Q01 20220.800.9316.25
Q04 20211.031.040.97
Q03 20210.941.028.51
Q02 20210.740.808.11
Q01 20210.640.7618.75
Q04 20200.760.805.26
Q03 20200.730.8313.70
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.88-10.20Negative
9/2022 QR1.11-9.02Negative
12/2022 FY4.13-3.95Negative
12/2023 FY4.66-4.70Negative
Next Report Date-
Estimated EPS Next Report0.88
Estimates Count9
EPS Growth Next 5 Years %12.60
Volume Overview
Volume2.03M
Shares Outstanding503.61K
Shares Float445.59M
Trades Count22.49K
Dollar Volume122.57M
Avg. Volume2.89M
Avg. Weekly Volume2.61M
Avg. Monthly Volume3.17M
Avg. Quarterly Volume2.87M

Baxter International Inc. (NYSE: BAX) stock closed at 60.46 per share at the end of the most recent trading day (a 0.82% change compared to the prior day closing price) with a volume of 2.03M shares and market capitalization of 30.45B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 50000 people. Baxter International Inc. CEO is Jose E. Almeida.

The one-year performance of Baxter International Inc. stock is -18.81%, while year-to-date (YTD) performance is -29.57%. BAX stock has a five-year performance of 1.04%. Its 52-week range is between 57.49 and 89.7, which gives BAX stock a 52-week price range ratio of 9.22%

Baxter International Inc. currently has a PE ratio of 30.00, a price-to-book (PB) ratio of 3.41, a price-to-sale (PS) ratio of 2.13, a price to cashflow ratio of 16.40, a PEG ratio of 2.32, a ROA of 3.93%, a ROC of 6.23% and a ROE of 11.65%. The company’s profit margin is 7.20%, its EBITDA margin is 18.50%, and its revenue ttm is $14.19 Billion , which makes it $28.18 revenue per share.

Of the last four earnings reports from Baxter International Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.88 for the next earnings report. Baxter International Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Baxter International Inc. is Moderate Buy (1.75), with a target price of $84.83, which is +40.31% compared to the current price. The earnings rating for Baxter International Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Baxter International Inc. has a dividend yield of 1.93% with a dividend per share of $1.16 and a payout ratio of 46.00%.

Baxter International Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 6.26, ATR14 : 1.44, CCI20 : -30.21, Chaikin Money Flow : -0.01, MACD : -1.84, Money Flow Index : 42.03, ROC : -9.49, RSI : 40.96, STOCH (14,3) : 31.02, STOCH RSI : 1.00, UO : 50.69, Williams %R : -68.98), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Baxter International Inc. in the last 12-months were: Albert P L Stroucken (Option Excercise at a value of $118 670), Albert P L Stroucken (Sold 4 020 shares of value $305 612 ), Brian C. Stevens (Sold 2 500 shares of value $213 757 ), Jacqueline Kunzler (Option Excercise at a value of $68 554), Jeanne K. Mason (Option Excercise at a value of $1 675 725), Jeanne K. Mason (Sold 54 143 shares of value $4 603 077 ), John D. Forsyth (Option Excercise at a value of $89 003), John D. Forsyth (Sold 3 015 shares of value $249 330 ), Peter S. Hellman (Option Excercise at a value of $118 670), Peter S. Hellman (Sold 4 020 shares of value $305 593 ), Sean B.W. Martin (Option Excercise at a value of $1 089 016), Sean B.W. Martin (Sold 21 450 shares of value $1 706 705 ), Thomas F. Chen (Option Excercise at a value of $58 850), Thomas F. Chen (Sold 1 680 shares of value $142 010 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (66.67 %)
8 (66.67 %)
9 (75.00 %)
Moderate Buy
1 (8.33 %)
1 (8.33 %)
1 (8.33 %)
Hold
2 (16.67 %)
2 (16.67 %)
1 (8.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (8.33 %)
1 (8.33 %)
1 (8.33 %)
Summary RatingModerate Buy
1.75
Moderate Buy
1.75
Strong Buy
1.58

Baxter International Inc.

Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2020 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while the acute therapies segment (6%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (23% of sales) sells IV pumps, administrative sets, and solutions while the nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (18% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostatic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.

CEO: Jose E. Almeida

Telephone: +1 224 948-2000

Address: One Baxter Parkway, Deerfield 60015, IL, US

Number of employees: 50 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

49%51%

Bearish Bullish

56%44%

Bearish Bullish

63%37%


News

Stocktwits